```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1646jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  DEC 08   INPADOC: Legal Status data reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added
 NEWS 14  OCT 21   BIOSIS file reloaded and enhanced
 NEWS 15  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS 16  NOV 24   MSDS-CCOHS file reloaded
 NEWS 17  DEC 08   CABA reloaded with left truncation
 NEWS 18  DEC 08   IMS file names changed
 NEWS 19  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 20  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 21  DEC 17   DGENE: Two new display fields added
 NEWS 22  DEC 18   BIOTECHNO no longer updated
 NEWS 23  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 24  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 25  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 26  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
```

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003

=> file medline caplus biosis embase cancerlit
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 18:05:19 ON 22 DEC 2003

FILE 'CAPLUS' ENTERED AT 18:05:19 ON 22 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 18:05:19 ON 22 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 18:05:19 ON 22 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003

=> s tnf or tumor (w)necrosis (w) factor
L1 333675 TNF OR TUMOR (W) NECROSIS (W) FACTOR

=> s (tnf or tumor (w)necrosis (w) factor) (w) antibodies
L2 918 (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES

=> l2 (S) (MIP-1b or RANTES)
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 (S) (MIP-1b or RANTES)
L3 2 L2 (S) (MIP-1B OR RANTES)

=> d l3 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
ACCESSION NUMBER: 96342263 EMBASE
DOCUMENT NUMBER: 1996342263
TITLE: Tumor necrosis factor (TNF) in inflammatory bowel disease: Gene polymorphisms, animal models, and potential for anti-TNF therapy.
AUTHOR: Stokkers P.C.F.; Camoglio L.; Van Deventer S.J.H.
CORPORATE SOURCE: Lab. for Experimental Internal Med., Meibergdreef 9,1105 AZ Amsterdam, Netherlands
SOURCE: Journal of Inflammation, (1995) 47/1-2 (97-103).
ISSN: 1078-7852 CODEN: JOINFB
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 026 Immunology, Serology and Transplantation
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The inflammatory bowel diseases frequently require surgery because of intestinal complications. Animal models of inflammatory bowel disease, in particular those that histopathologically resemble Crohn's disease, are characterized by increased mucosal TNF production, and anti-**TNF**

antibodies have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotherapy of Crohn's disease. Administration of anti-**TNF antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing **RANTES** and MIP-1. Short-term treatment with anti-**TNF antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulaton in Crohn's disease.

L3 ANSWER 2 OF 2 CANCERLIT on STN
ACCESSION NUMBER: 97071010 CANCERLIT
DOCUMENT NUMBER: 97071010 PubMed ID: 8913936
TITLE: Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy.
AUTHOR: Stokkers P C; Camoglio L; van Deventer S J
CORPORATE SOURCE: Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
SOURCE: JOURNAL OF INFLAMMATION, (1995-96) 47 (1-2) 97-103. Ref: 54
Journal code: 9511967. ISSN: 1078-7852.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: MEDLINE; Priority Journals
OTHER SOURCE: MEDLINE 97071010
ENTRY MONTH: 199702
ENTRY DATE: Entered STN: 19970305
Last Updated on STN: 19970305
AB The inflammatory bowel diseases frequently require surgery because of intestinal complications. Animal models of inflammatory bowel disease, in particular those that histopathologically resemble Crohn's disease, are characterized by increased mucosal TNF production, and anti-**TNF antibodies** have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotheraphy of Crohn's disease. Administration of anti-**TNF antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing **RANTES** and MIP-1. Short-term treatment with anti-**TNF antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulation in Crohn's disease.

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003
L1 333675 S TNF OR TUMOR (W)NECROSIS (W) FACTOR
L2 918 S (TNF OR TUMOR (W)NECROSIS (W) FACTOR) (W) ANTIBODIES

```
L3            2 S L2 (S) (MIP-1B OR RANTES)

=> s l1 S (fusion or conjugate) s chemokine?
MISSING OPERATOR L1 S
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s s l1 S (fusion or conjugate)
MISSING OPERATOR S L1
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 (s) (fusion? or conjugate?)
L4         3699 L1 (S) (FUSION? OR CONJUGATE?)

=> s l4 (s) chemokine?
L5           42 L4 (S) CHEMOKINE?

=> s l5 (s) antibodies
L6            5 L5 (S) ANTIBODIES

=> duplicate remove l6
DUPLICATE PREFERENCE IS 'EMBASE, CANCERLIT'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L6
L7            3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> d l7 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L7   ANSWER 1 OF 3  EMBASE  COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
AN   2003161017  EMBASE
TI   Cytokine, chemokine, and costimulatory molecule modulation to enhance
     efficacy of HIV vaccines.
AU   Ahlers J.D.; Belyakov I.M.; Berzofsky J.A.
CS   J.A. Berzofsky, Molec. Immunogen./Vaccine Res. Sec., Metabolism Branch,
     National Cancer Institute, Building 10, Bethesda, MD 20892-1578, United
     States. jahlers@niaid.nih.gov
SO   Current Molecular Medicine, (2003) 3/3 (285-301).
     Refs: 206
     ISSN: 1566-5240  CODEN: CMMUBP
CY   Netherlands
DT   Journal; General Review
FS   004     Microbiology
     026     Immunology, Serology and Transplantation
     030     Pharmacology
     037     Drug Literature Index
     039     Pharmacy
LA   English
SL   English

L7   ANSWER 2 OF 3  EMBASE  COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN                                              DUPLICATE 1
AN   2001154626  EMBASE
TI   Anti-TNF.alpha. therapy of rheumatoid arthritis: What have we learned?.
AU   Feldmann M.; Maini R.N.
CS   M. Feldmann, Kennedy Inst. of Rheumatology Div., Imperial College School
     of Medicine, 1 Aspenlea Road, London W6 8LH, United Kingdom.
     m.feldmann@ic.ac.uk
SO   Annual Review of Immunology, (2001) 19/- (163-196).
     Refs: 160
     ISSN: 0732-0582  CODEN: ARIMDU
CY   United States
DT   Journal; General Review
```

FS 026 Immunology, Serology and Transplantation
031 Arthritis and Rheumatism
037 Drug Literature Index
LA English
SL English

L7 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN DUPLICATE 2
AN 1998362492 EMBASE
TI Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow.
AU Fong A.M.; Robinson L.A.; Steeber D.A.; Tedder T.F.; Yoshie O.; Imai T.; Patel D.D.
CS D.D. Patel, Box 3258, 222 CARL Bldg., Duke University Medical Center, Durham, NC 27710, United States. patel003@mc.duke.edu
SO Journal of Experimental Medicine, (19 Oct 1998) 188/8 (1413-1419).
Refs: 28
ISSN: 0022-1007 CODEN: JEMEAV
CY United States
DT Journal; Article
FS 025 Hematology
029 Clinical Biochemistry
LA English
SL English

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003
L1 333675 S TNF OR TUMOR (W)NECROSIS (W) FACTOR
L2 918 S (TNF OR TUMOR (W)NECROSIS (W) FACTOR) (W) ANTIBODIES
L3 2 S L2 (S) (MIP-1B OR RANTES)
L4 3699 S L1 (S) (FUSION? OR CONJUGATE?)
L5 42 S L4 (S) CHEMOKINE?
L6 5 S L5 (S) ANTIBODIES
L7 3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.13	50.34

STN INTERNATIONAL LOGOFF AT 18:16:58 ON 22 DEC 2003